Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent

JACC: Cardiovascular Imaging

Volumn 7, Issue 1, 2014, Pages 40-48

  Main, Michael L ^a   Hibberd, Mark G ^b   Ryan, Amy ^c   Lowe, Timothy J ^c   Miller, Paula ^b   Bhat, Gajanan ^b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b Clinical Research   (United States)

^c Premier Inc   (United States)

Author keywords

contrast echocardiography; contrast enhanced ultrasound; ultrasound contrast agents

Indexed keywords

ECHO CONTRAST MEDIUM; CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSTHORACIC ECHOCARDIOGRAPHY; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; CRITICAL ILLNESS; ECHOCARDIOGRAPHY; EPIDEMIOLOGY; FOLLOW UP; HOSPITAL MORTALITY; LENGTH OF STAY; MORTALITY; MULTICENTER STUDY; ODDS RATIO; PROCEDURES; PROGNOSIS; PROPENSITY SCORE; RISK FACTOR; SURVIVAL RATE; TRENDS; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CONTRAST MEDIA; CRITICAL ILLNESS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84892517381     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2013.08.012     Document Type: Article

References (12)

1. M. Kurt, K.A. Shaikj, and L. Peterson et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospect cohort J Am Coll Cardiol 53 2009 802 810
2. D.W. Kitzman, M.E. Goldman, and L.D. Gillam et al. Efficacy and safety of the novel ultrasound contrast agent Perflutren (Definity) in patients with suboptimal baseline left ventricular echocardiographic images Am J Cardiol 86 2000 669 674
3. S.L. Mulvagh, H. Rakowski, and M.A. Vannan et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography J Am Soc Echocardiogr 21 2008 1179 1201
4. P.S. Douglas, M.R. Garcia, and D.E. Haines et al. ACCF/ASE/AHA/ASNC/HFSA/ HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate use criteria for echocardiography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance J Am Coll Cardiol 57 2011 1126 1166
5. M.L. Main, A.C. Ryan, T.E. Davis, M.P. Albano, L.L. Kusnetzky, and M. Hibberd Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients) Am J Cardiol 102 2008 1742 1746
6. P.J. Wickramaratne Sample size determination in epidemiologic studies Stat Methods Med Res 4 1995 311 337
7. A.V. Alexandrov, R. Mikulik, and M. Ribo et al. A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke Stroke 39 2008 1464 1469
8. R.B. D'Agostino Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
9. P.C. Austin An introduction to propensity score methods for reducing the effects of confounding in observational studies Multivariate Behav Res 46 2011 399 424
10. U.S. Food and Drug Administration. Micro-bubble Contrast Agents (marketed as Definity (Perflutren Lipid Microspheres) Injectable Suspension and Optison (Perflutren Protein Type-A Microspheres for Injection) October 2007. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm152686.htm. Accessed April 17, 2013.
11. L.L. Kusnetzky, A. Khalid, T.M. Khumri, T.G. Moe, P.G. Jones, and M.L. Main Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 patients J Am Cardiol Coll 51 2008 1704 1706
12. A. Exuzides, M.L. Main, C. Colby, P.A. Grayburn, S.B. Feinstein, and J.H. Goldman A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent J Am Coll Cardiol Img 3 2010 578 585